Airway Therapeutics Secures $50 Million for Preterm Infant Lung Therapy
August 27, 2026, 3:36 pm
Location: United States, Ohio, Cincinnati
Employees: 10001+
Founded date: 1883
Total raised: $30.2M
Location: United States, Ohio, Cincinnati
Employees: 11-50
Founded date: 2011
Total raised: $76.9M
Airway Therapeutics closed a $50 million financing round. This capital injection accelerates late-stage development of zelpultide alfa. The novel biologic aims to prevent bronchopulmonary dysplasia (BPD) in very preterm infants. BPD currently lacks any approved preventive therapies. Funds will primarily support completion of the Phase 2b portion of its ongoing Phase 2b/3 clinical trial. They also cover chemistry, manufacturing, and controls (CMC) activities. Analytical work for a potential biologics license application (BLA) is also funded. An interim analysis from the Phase 2b study is anticipated by Q2 2027. Zelpultide alfa functions by regulating immune responses, enhancing pathogen clearance, and maintaining pulmonary surfactant homeostasis. This significant funding addresses a critical unmet medical need.
Airway Therapeutics, a leading biopharmaceutical firm, announced a major funding milestone. The Atlanta-based company secured $50 million. This capital fuels its critical mission. It advances a pioneering therapy for very preterm infants.
The funding directly supports zelpultide alfa. This investigational drug targets bronchopulmonary dysplasia (BPD). BPD is a severe, chronic lung disease. It devastates infants born prematurely. Current medical options offer no approved preventive therapies. This represents a profound unmet medical need. Airway Therapeutics is poised to transform this landscape.
Zelpultide alfa embodies a new class of biologic therapies. It is an engineered recombinant human surfactant protein D (rhSP-D). This protein closely mimics a natural lung protein. Its design ensures specific, vital biological functions. The innovative therapy operates via multiple mechanisms. It actively regulates immune responses. This action significantly reduces excessive inflammation. It also markedly improves pathogen recognition. Pathogen clearance within the lungs is enhanced. Maintaining surfactant homeostasis forms another key function. This supports robust pulmonary function. These actions are paramount for vulnerable, developing infant lungs.
The $50 million financing comprises distinct components. A $26 million SAFE (Simple Agreement for Future Equity) financing was previously secured. An additional $24 million stemmed from a Series E-2 round. Most existing investors showed strong commitment. Roughly 94% of Airway’s current backers participated in the Series E-2 financing. Notable investors included Cincinnati Children’s. A syndicate of prominent family offices also joined. This broad support underscores significant investor confidence.
Proceeds from this latest funding round have defined, critical objectives. The primary goal centers on completing the Phase 2b portion. This crucial segment is part of Airway’s ongoing Phase 2b/3 trial. The trial rigorously evaluates zelpultide alfa's efficacy and safety. Advancing clinical development remains paramount.
Beyond the core trial, funds support essential peripheral areas. Chemistry, Manufacturing, and Controls (CMC) activities are vital. These ensure the drug’s consistent quality. They guarantee reliable production. Analytical work also receives funding. This crucial work prepares for a potential Biologics License Application (BLA). The BLA submission is a pivotal step for market approval. Airway Therapeutics aims for a disciplined, efficient development trajectory.
An important program milestone rapidly approaches. Airway Therapeutics anticipates an interim analysis. This analysis marks the successful completion of the Phase 2b study portion. The projected timeline targets the end of the second quarter of 2027. Positive results could dramatically accelerate the program. They would provide critical data for subsequent development stages.
Bronchopulmonary dysplasia (BPD) remains a grave concern globally. It impacts tens of thousands of preterm infants annually. This debilitating disease can lead to lifelong respiratory complications. Its effective prevention stands as a major public health priority. Airway Therapeutics directly addresses this immense challenge. The company’s unwavering focus on BPD highlights its commitment. It seeks innovative solutions for the most vulnerable populations.
The company’s advanced platform utilizes zelpultide alfa. It is designed for broad therapeutic application. Its inherent properties suggest benefits across various respiratory conditions. It might also prove effective in inflammatory and infectious diseases. However, the immediate, strategic focus is BPD prevention. This targeted approach addresses an area of exceptionally high unmet need.
Airway Therapeutics operates at the forefront of biologic innovation. Its experienced leadership guides its progress. Chairman and CEO Marc Salzberg, MD, spearheads the team. The company builds on solid previous clinical success. A prior Phase 1b study demonstrated a favorable safety profile for zelpultide alfa. This foundational work underpins the current late-stage trial.
This substantial capital infusion positions Airway Therapeutics robustly. It ensures sustained development momentum. The company progresses its late-stage clinical program with purpose. Evaluating zelpultide alfa for BPD prevention is its core mission. The population of very preterm infants faces a significant medical challenge. This advanced therapy offers new, crucial hope.
This recent funding round underscores robust investor belief. It demonstrates confidence in Airway’s proprietary technology. It also signals strong faith in its meticulous clinical strategy. The ultimate goal is clear: bring a preventive therapy to market. This achievement would revolutionize care for preterm babies. It would set a new, higher standard in neonatology.
The broader biotech sector watches closely. Success for zelpultide alfa could pave the way. It might open new avenues for similar biologic interventions. These interventions would target complex pediatric conditions. The implications extend well beyond BPD. They touch upon broader respiratory health advancements.
Airway Therapeutics continues its rigorous development path. The coming year will be pivotal. The interim analysis will serve as a critical data point. Future regulatory submissions depend heavily on its outcomes. This new financing ensures the company possesses necessary resources. It moves closer to its ambitious goal. It aims to deliver a true breakthrough. This breakthrough could save lives. It could vastly improve countless others. The global fight against BPD gains crucial, decisive momentum.
Airway Therapeutics, a leading biopharmaceutical firm, announced a major funding milestone. The Atlanta-based company secured $50 million. This capital fuels its critical mission. It advances a pioneering therapy for very preterm infants.
The funding directly supports zelpultide alfa. This investigational drug targets bronchopulmonary dysplasia (BPD). BPD is a severe, chronic lung disease. It devastates infants born prematurely. Current medical options offer no approved preventive therapies. This represents a profound unmet medical need. Airway Therapeutics is poised to transform this landscape.
Zelpultide alfa embodies a new class of biologic therapies. It is an engineered recombinant human surfactant protein D (rhSP-D). This protein closely mimics a natural lung protein. Its design ensures specific, vital biological functions. The innovative therapy operates via multiple mechanisms. It actively regulates immune responses. This action significantly reduces excessive inflammation. It also markedly improves pathogen recognition. Pathogen clearance within the lungs is enhanced. Maintaining surfactant homeostasis forms another key function. This supports robust pulmonary function. These actions are paramount for vulnerable, developing infant lungs.
The $50 million financing comprises distinct components. A $26 million SAFE (Simple Agreement for Future Equity) financing was previously secured. An additional $24 million stemmed from a Series E-2 round. Most existing investors showed strong commitment. Roughly 94% of Airway’s current backers participated in the Series E-2 financing. Notable investors included Cincinnati Children’s. A syndicate of prominent family offices also joined. This broad support underscores significant investor confidence.
Proceeds from this latest funding round have defined, critical objectives. The primary goal centers on completing the Phase 2b portion. This crucial segment is part of Airway’s ongoing Phase 2b/3 trial. The trial rigorously evaluates zelpultide alfa's efficacy and safety. Advancing clinical development remains paramount.
Beyond the core trial, funds support essential peripheral areas. Chemistry, Manufacturing, and Controls (CMC) activities are vital. These ensure the drug’s consistent quality. They guarantee reliable production. Analytical work also receives funding. This crucial work prepares for a potential Biologics License Application (BLA). The BLA submission is a pivotal step for market approval. Airway Therapeutics aims for a disciplined, efficient development trajectory.
An important program milestone rapidly approaches. Airway Therapeutics anticipates an interim analysis. This analysis marks the successful completion of the Phase 2b study portion. The projected timeline targets the end of the second quarter of 2027. Positive results could dramatically accelerate the program. They would provide critical data for subsequent development stages.
Bronchopulmonary dysplasia (BPD) remains a grave concern globally. It impacts tens of thousands of preterm infants annually. This debilitating disease can lead to lifelong respiratory complications. Its effective prevention stands as a major public health priority. Airway Therapeutics directly addresses this immense challenge. The company’s unwavering focus on BPD highlights its commitment. It seeks innovative solutions for the most vulnerable populations.
The company’s advanced platform utilizes zelpultide alfa. It is designed for broad therapeutic application. Its inherent properties suggest benefits across various respiratory conditions. It might also prove effective in inflammatory and infectious diseases. However, the immediate, strategic focus is BPD prevention. This targeted approach addresses an area of exceptionally high unmet need.
Airway Therapeutics operates at the forefront of biologic innovation. Its experienced leadership guides its progress. Chairman and CEO Marc Salzberg, MD, spearheads the team. The company builds on solid previous clinical success. A prior Phase 1b study demonstrated a favorable safety profile for zelpultide alfa. This foundational work underpins the current late-stage trial.
This substantial capital infusion positions Airway Therapeutics robustly. It ensures sustained development momentum. The company progresses its late-stage clinical program with purpose. Evaluating zelpultide alfa for BPD prevention is its core mission. The population of very preterm infants faces a significant medical challenge. This advanced therapy offers new, crucial hope.
This recent funding round underscores robust investor belief. It demonstrates confidence in Airway’s proprietary technology. It also signals strong faith in its meticulous clinical strategy. The ultimate goal is clear: bring a preventive therapy to market. This achievement would revolutionize care for preterm babies. It would set a new, higher standard in neonatology.
The broader biotech sector watches closely. Success for zelpultide alfa could pave the way. It might open new avenues for similar biologic interventions. These interventions would target complex pediatric conditions. The implications extend well beyond BPD. They touch upon broader respiratory health advancements.
Airway Therapeutics continues its rigorous development path. The coming year will be pivotal. The interim analysis will serve as a critical data point. Future regulatory submissions depend heavily on its outcomes. This new financing ensures the company possesses necessary resources. It moves closer to its ambitious goal. It aims to deliver a true breakthrough. This breakthrough could save lives. It could vastly improve countless others. The global fight against BPD gains crucial, decisive momentum.